Patents Assigned to Amgen
  • KIF18A INHIBITORS FOR TREATMENT OF NEOPLASTIC DISEASES
    Publication number: 20230151432
    Abstract: Provided herein are methods of treating a subject having a neoplastic disease, comprising administering to the subject a KIF18A inhibitor in an amount effective to treat the neoplastic disease a neoplastic disease in a subject. Also provided are methods of inducing or increasing tumor regression in a subject with a tumor and methods of reducing tumor or cancer growth in a subject. In exemplary aspects, the method comprises administering to the subject a KIF18A inhibitor. Methods of inducing or increasing death of tumor or cancer cells in a subject comprising administering to the subject a KIF18A inhibitor are also provided herein. Advantageously, the KIF18A inhibitors selectively treat the neoplastic disease, induce or increase tumor regression, and/or induce or increase death of tumor or cancer cells without overt toxicity to normal somatic cells.
    Type: Application
    Filed: April 13, 2021
    Publication date: May 18, 2023
    Applicant: AMGEN INC.
    Inventor: Marc Noel PAYTON
  • GROWTH DIFFERENTIATION FACTOR 15 FUSION PROTEINS
    Publication number: 20230143988
    Abstract: GDF15 molecules are provided herein. In some embodiments, the GDF15 molecule is a GDF15-Fc fusion, in which a GDF15 region is fused to an Fc region. In some embodiments, the GDF15 region is fused to the Fc region via a linker. Also, provided herein are methods for making and using GDF15 molecules.
    Type: Application
    Filed: April 8, 2019
    Publication date: May 11, 2023
    Applicant: AMGEN INC.
    Inventors: YuMei XIONG, Kenneth William WALKER, Murielle Marie VENIANT ELLISON
  • Peptide PAC1 antagonists
    Patent number: 11643440
    Abstract: Novel peptides that bind to human PAC1 are provided. These peptides that are antagonists of PAC1 are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine, such as acute migraine.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: May 9, 2023
    Assignee: AMGEN INC.
    Inventors: Irwin Chen, Su Chong, Essa Hu Harrington, Fang-Tsao Hong, Jason C. Long, Leslie P. Miranda
  • METHODS OF TREATING GRAFT VERSUS HOST DISEASE USING IL-2 MUTEINS
    Publication number: 20230139534
    Abstract: Described herein are immunosuppressive molecules including immunosuppressive variants of IL-2, and use of such molecules to treat inflammatory and autoimmune disorders.
    Type: Application
    Filed: December 20, 2022
    Publication date: May 4, 2023
    Applicant: Amgen Inc.
    Inventors: Marc A. GAVIN, Li LI
  • BISPECIFIC OR BIPARATOPIC ANTIGEN BINDING PROTEINS AND USES THEREOF
    Publication number: 20230137351
    Abstract: The present invention relates to bispecific or biparatopic antigen binding proteins, polynucleotides encoding the same, and methods of making bispecific or biparatopic antigen binding proteins. Also described herein is a method to assemble IgG-like biparatopic or bispecific antibodies from VH only antigen binding proteins.
    Type: Application
    Filed: November 14, 2017
    Publication date: May 4, 2023
    Applicant: AMGEN INC.
    Inventors: Wei YAN, Zhi LIU, Christopher MURAWSKY, Chadwick Terence KING, Yang LI, Zhonghua HU, Desiree LIM
  • Synthesis of vinylic alcohol intermediates
    Publication number: 20230136910
    Abstract: Provided herein are processes for synthesizing intermediates useful in preparing Mcl-1 inhibitors. In particular, provided herein are processes for synthesizing compound (E), wherein R1 is described herein. Compound (E) can be useful in synthesizing compound (A1), or a salt or solvate thereof, and compound (A2), or a salt of solvate thereof.
    Type: Application
    Filed: April 28, 2021
    Publication date: May 4, 2023
    Applicant: AMGEN INC.
    Inventors: Robert P. FARRELL, Jason S. TEDROW
  • Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases
    Patent number: 11639332
    Abstract: Provided herein are azo prodrugs of small-molecule isoindoline-1,3-diones and isoindoles anti-inflammatory inhibitors according to formula IA, in particular PDE4 inhibitors, which prodrugs can be administered orally to a subject in need thereof, whereby the prodrugs are cleaved in the colon and the PDE4 inhibitor released.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: May 2, 2023
    Assignees: AMGEN (EUROPE) GMBH
    Inventor: William R. Baker
  • PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF
    Publication number: 20230128444
    Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
    Type: Application
    Filed: September 28, 2022
    Publication date: April 27, 2023
    Applicant: AMGEN INC.
    Inventors: Hailing HSU, Ming ZHANG, Gunasekaran KANNAN, Frederick W. JACOBSEN, Wayne H. TSUJI
  • MAMMALIAN CELL CULTURE
    Publication number: 20230129523
    Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell o growth to achieve high product titer cell cultures.
    Type: Application
    Filed: December 20, 2022
    Publication date: April 27, 2023
    Applicant: AMGEN INC.
    Inventors: Brian D. FOLLSTAD, Rebecca E. McCOY, Arvia E. MORRIS
  • Prevention of adverse effects caused by CD3 specific binding domains
    Patent number: 11633408
    Abstract: The present invention relates to a glucocorticoid (GC) for use in the amelioration, treatment or prophylaxis of neurological/psychiatric adverse events caused by a CD3 binding domain. Kits comprising a GC, a CD3 binding domain and instructions for use which indicate that the GC is to be employed for the treatment amelioration and/or prophylaxis of neurological adverse events caused by said CD3 binding domain, are also disclosed.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: April 25, 2023
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Gerhard Zugmaier, Dirk Nagorsen, Juergen Scheele
  • Drug injection device with visual and audio indicators
    Patent number: 11633548
    Abstract: A drug injection device (10) including a housing (12) for holding a container (20) having a needle (24) for penetrating skin and a plunger (42) for expelling a drug stored in the container. The device includes visual and/or audible indicators for indicating that the correct depth of needle penetration has been achieved and that drug injection/extrusion has been started and/or completed. The device may further include a label (140) for visually confirming the quality of the drug contained therein. Alternatively, a tray (110) may be provided for receiving the drug injection device, which allows the quality of the drug contained therein to be visually confirmed.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: April 25, 2023
    Assignee: AMGEN INC.
    Inventors: Peter V. Shultz, Christopher R. Folk, Sigrid Moeslinger, Masamichi Udagawa, Molly Evans, Lin Gao, Lisa Nugent
  • Mammalian cell culture
    Patent number: 11634476
    Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: April 25, 2023
    Assignee: AMGEN INC.
    Inventors: Brian D. Follstad, Rebecca E. McCoy, Arvia E. Morris
  • Heterodimeric bispecific antibodies
    Patent number: 11634502
    Abstract: Provided herein are heterodimeric bispecific antibodies that can mediate cytolysis of a target cell by an immune effector cell, nucleic acids encoding such antibodies, methods of making such antibodies, and methods of using such antibodies. These antibodies comprise two different polypeptide chains, each comprising two immunoglobulin variable regions and, optionally, a half life-extending moiety.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: April 25, 2023
    Assignee: AMGEN INC.
    Inventors: Wei Yan, Martin J. Pentony, Luis G. Borges, Mark L. Michaels
  • MAMMALIAN CELL CULTURE
    Publication number: 20230117598
    Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures.
    Type: Application
    Filed: December 14, 2022
    Publication date: April 20, 2023
    Applicant: AMGEN INC.
    Inventors: Brian D. FOLLSTAD, Rebecca E. McCOY, Arvia E. MORRIS
  • COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS
    Publication number: 20230121955
    Abstract: The present invention provides combination therapy that includes an KRASG12C inhibitor, such as or a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
    Type: Application
    Filed: July 21, 2022
    Publication date: April 20, 2023
    Applicant: Amgen Inc.
    Inventors: James Russell LIPFORD, Jude Robert CANON, Anne Y. SAIKI, Karen Louise REX
  • METHYLATION OF MCL-1 COMPOUNDS
    Publication number: 20230117777
    Abstract: Disclosed herein is an improved process for the synthesis of compound (A): (A), or a salt or solvate thereof via methylation of compound (B): (B), or a salt or solvate thereof, a crystalline hydrate of compound A, and pharmaceutical formulations comprising a crystalline hydrate of compound (A).
    Type: Application
    Filed: March 30, 2021
    Publication date: April 20, 2023
    Applicant: AMGEN INC.
    Inventors: Michal ACHMATOWICZ, Sheng CUI, Tsang-Lin HWANG, Neil Fred LANGILLE, Janine K. TOM, James E. HUCKLE, Markian STEC, Tian WU, Sean P. BROWN
  • Handheld drug delivery device
    Patent number: D985116
    Type: Grant
    Filed: March 10, 2021
    Date of Patent: May 2, 2023
    Assignee: AMGEN INC.
    Inventors: Austin Davis, Lars Eilertsen, David Lavmand Muller, Rasmus Øhlenschlæger, Gregory Thomas Nowak, Kasper Poder, Dylan Bourelle
  • Handheld drug delivery device
    Patent number: D985117
    Type: Grant
    Filed: March 10, 2021
    Date of Patent: May 2, 2023
    Assignee: AMGEN INC.
    Inventors: Austin Davis, Lars Eilertsen, David Lavmand Muller, Rasmus Øhlenschlæger, Gregory Thomas Nowak, Kasper Poder, Dylan Bourelle
  • Handheld drug delivery device
    Patent number: D985118
    Type: Grant
    Filed: March 10, 2021
    Date of Patent: May 2, 2023
    Assignee: AMGEN INC.
    Inventors: Austin Davis, Lars Eilertsen, David Lavmand Muller, Rasmus Øhlenschlæger, Gregory Thomas Nowak, Kasper Poder, Dylan Bourelle
  • Handheld drug delivery device
    Patent number: D985119
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: May 2, 2023
    Assignee: AMGEN INC.
    Inventors: Matias Melander, Bjarke Lykke Ludvig Svendsen, Christian Plambech, Michael Sorensen, Dylan Bourelle